不同联合用药方案对中老年幽门螺杆菌感染患者的有效性、安全性及经济性对比

Comparison on Effectiveness,Safety and Economy of Different Combination Medication Regimens for Middleaged and Elderly Patientswith Helicobacter Pylori Infection

目的:探讨不同联合用药方案对中老年幽门螺杆菌(Hp)感染患者的有效性、安全性及经济性。方法:回顾性分析我院2018年6月至2019年6月100例确诊为老年幽门螺杆菌(Hp)感染患者的病历资料,按照实际用药方案不同分为A组(n=50)和B组(n=50),A组给予克拉霉素+阿莫西林+奥美拉唑+铋剂治疗,B组采用呋喃唑酮+阿莫西林+雷贝拉唑+铋剂治疗。比较两组有效性、安全性及经济性。结果:B组临床治疗有效率96.00%高于A组84.00%(P<0.05);B组幽门螺杆菌根除率92.00%高于A组72.00%(P<0.05);B组不良反应发生率8.00%低于A组24.00%(P<0.05);B组用药成本小于于A组(P<0.05)。结论:针对中老年Hp感染患者,呋喃唑酮+阿莫西林+雷贝拉唑+铋剂方案治疗效果更为确切,成本更低,且安全性高,具有更高合理性。

Objective: To explore effectiveness, safety and economy of different combination medication regimens for middle-aged and elderly patients with Helicobacter pylori(Hp)infection. Methods: A retrospective analysis was performed on the medical records of 100 elderly patients withHp infection who were confirmed in the hospital from June 2018 to June 2019. According to different actual medication regimens, they were divided into group A(n=50)and group B(n=50). Group A was treated with clarithromycin+amoxicillin+omeprazole+bismuth, while group B was treated with furazo lidone+amoxicillin+rabeprazole+bismuth. The effectiveness, safety and economy were compared between the two groups. Results: The response rate of clinical treatment in group B was higher than that in group A(96.00% vs 84.00%)(P<0.05). The Hperadication rate in group B was higher than that in group A(92.00% vs 72.00%)(P<0.05). The incidence of adverse reactions in group B waslower than that in group A(8.00% vs 24.00%)(P<0.05). The medication cost of group B was less than that of group A(P<0.05). Conclusion: For middle-aged and elderly patients with Hp infection, curative effect of furazolidone+amoxicillin+rabeprazole+bismuthis more significant, cost is lower, safety is higher, which is more reasonable.